Triple

T6311255
Position Surface form Disambiguated ID Type / Status
Subject Novartis E141505 entity
Predicate notableDrug P7501 FINISHED
Object Entresto
Entresto is a prescription heart failure medication that combines sacubitril and valsartan to reduce the risk of cardiovascular death and hospitalization.
 E584152 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Entresto | Statement: [Novartis, notableDrug, Entresto]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Entresto
Context triple: [Novartis, notableDrug, Entresto]
  • A. Brilinta
    Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
  • B. Farxiga
    Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
  • C. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • D. Evrysdi
    Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
  • E. Vitrakvi
    Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Entresto
Triple: [Novartis, notableDrug, Entresto]
Generated description
Entresto is a prescription heart failure medication that combines sacubitril and valsartan to reduce the risk of cardiovascular death and hospitalization.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Entresto
Target entity description: Entresto is a prescription heart failure medication that combines sacubitril and valsartan to reduce the risk of cardiovascular death and hospitalization.
  • A. Brilinta
    Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
  • B. Farxiga
    Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
  • C. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • D. Evrysdi
    Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
  • E. Vitrakvi
    Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c008d00efc8190a36c05b4b4a3bf4b completed March 22, 2026, 3:20 p.m.
NER Named-entity recognition batch_69c0649d1e048190a3fc7fbce9d2ee57 completed March 22, 2026, 9:52 p.m.
NED1 Entity disambiguation (via context triple) batch_69c5e461e2ec8190af7198a03edb1ff7 completed March 27, 2026, 1:58 a.m.
NEDg Description generation batch_69c5e66e8b3c8190bd4cd960b91de473 completed March 27, 2026, 2:07 a.m.
NED2 Entity disambiguation (via description) batch_69c5e6e40c588190898ad952b71e5b11 completed March 27, 2026, 2:09 a.m.
Created at: March 22, 2026, 4:28 p.m.